



May 18, 2015

## Foundation Medicine and Collaborators to Present Data in 22 Oral and Poster Presentations at the 2015 ASCO Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- [Foundation Medicine, Inc.](#) (NASDAQ:FMI) today announced that the company and its collaborators will present 22 oral and poster presentations at the 2015 American Society for Clinical Oncology (ASCO) Annual Meeting taking place May 29 - June 2, 2015 in Chicago.

"Since Foundation Medicine launched its flagship product, FoundationOne®, at ASCO three years ago, we have continued to provide high-quality, high-impact data to support and advance the transformation of cancer care," said Vincent Miller, M.D., chief medical officer, Foundation Medicine. "This year, much of our data focuses on tumors that remain therapeutic challenges such as non-small cell lung cancer and others that are similarly arduous but under studied, including biliary tract and AYA malignancies. We believe our data demonstrate the power of molecular information in guiding identification, characterization and treatment of difficult cancers, and ultimately, accelerating precision medicine and better outcomes in cancer care."

The company's molecular information products, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer. The data to be presented at ASCO provide further evidence of the clinical utility of Foundation Medicine's comprehensive genomic profiles to identify the molecular alterations in patient's cancer and aid in the development of targeted therapies.

The schedule for oral presentations by Foundation Medicine and/or its collaborators is as follows:

**Date & Time:** Sunday, May 31, 2015 from 4:30-4:42 p.m. CT

**Title:** Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific difference and frequency of clinically relevant genomic alterations

**Abstract:** 4009

**Location:** E Hall D2

**Session:** To Lump or To Split: Molecular, Anatomic, and Etiologic Subtyping of Noncolorectal Gastrointestinal Malignancies and Potential Therapeutic Implications

**Presenter:** Milind Javle, M.D., The University of Texas MD Anderson Cancer Center

**Collaborators:** Albany Medical College, The University of Texas MD Anderson Cancer Center, University of Chicago

**Date & Time:** Monday, June 1, 2015 from 10:24-10:36 a.m. CT

**Title:** Results of ARIEL2: a Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis

**Abstract:** 5508

**Location:** E354b

**Session:** Gynecological Cancer

**Presenter:** Iain A. McNeish, Ph.D., Institute of Cancer Sciences, University of Glasgow

**Collaborators:** Institute of Cancer Sciences - University of Glasgow, Princess Margaret Cancer Centre, The University of Texas MD Anderson Cancer Center, Royal Melbourne Hospital, University of California - Los Angeles, British Columbia Cancer Agency, The Ohio State University College of Medicine, Cancer Research UK Cambridge Institute, University College London Cancer Institute, Memorial Sloan Kettering Cancer Center, Vall d'Hebron University Hospital, Institut Gustave Roussy, Clovis Oncology, University of Washington School of Medicine

**Date & Time:** Monday, June 1, 2015 from 5:12-5:24 p.m. CT

**Title:** Comprehensive genomic profiling (CGP) of advanced cancers to identify MET exon 14 alterations that confer sensitivity to MET inhibitors

**Abstract:** 11007

**Location:** E450

**Session:** Tumor Biology

**Presenter:** Sai-Hong Ignatius Ou, M.D., Ph.D., University of California Irvine

**Collaborators:** University of California at Los Angeles, University of North Carolina at Chapel Hill, Michiana Hematology Oncology PC, University of Chicago, University of Miami Sylvester Comprehensive Cancer Center, Texas Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Albany Medical College, University of California Irvine Health Chao Family Comprehensive Cancer Center

The schedule for poster discussions and poster presentations by Foundation Medicine and/or its collaborators is as follows:

**Poster Display:** Sunday, May 31, 2015 from 8:00 a.m.-12:45 p.m. CT

**Poster Presentation:** Sunday, May 31, 2015 from 11:30 a.m.-12:45 p.m. CT

**Title:** Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy

**Abstract:** 11019

**Poster Board:** 231

**Poster Display Location:** S Hall A

**Poster Presentation Location:** S406

**Session:** Tumor Biology

**Presenter:** Jennifer J. Wheler, M.D., The University of Texas MD Anderson Cancer Center

**Collaborators:** The University of Texas MD Anderson Cancer Center, Department of Investigational Therapeutics (Phase 1 Program) - Sarah Cannon Research Institute at HealthOne, University of California San Diego

**Poster Display:** Sunday, May 31, 2015 from 8:00-11:30 a.m. CT

**Poster Discussion:** Sunday, May 31, 2015 from 11:30 a.m.-12:45 p.m. CT

**Title:** Comprehensive genomic profiling of sarcomas from 267 adolescents and young adults to reveal a spectrum of targetable genomic alterations

**Abstract:** 11020

**Poster Board:** 232

**Poster Display Location:** S Hall A

**Poster Discussion Location:** S406

**Session:** Tumor Biology

**Presenter:** Deborah Morosini, M.D., vice president, clinical development, Foundation Medicine

**Collaborators:** Albany Medical College, Oregon Health and Science University

**Poster Display:** Monday, June 1, 2015 from 1:15-4:45 p.m. CT

**Poster Discussion:** Monday, June 1, 2015 from 4:45-6:00 p.m. CT

**Title:** Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer

**Abstract:** 4514

**Poster Board:** 184

**Poster Display Location:** S Hall A

**Poster Discussion Location:** E Arie Crown Theatre

**Session:** Genitourinary (Nonprostate) Cancer

**Presenter:** Yu-Ning Wong, M.D., Fox Chase Cancer Center

**Collaborators:** Fox Chase Cancer Center, Temple University Health System, The Sidney Kimmel Cancer Center at Thomas Jefferson University

**Poster Display:** Monday, June 1, 2015 from 1:15-4:45 p.m. CT

**Poster Discussion:** Monday, June 1, 2015 from 4:45-6:00 p.m. CT

**Title:** Comprehensive genomic profiling of 443 patients with advanced renal cell carcinoma (RCC) to reveal clinically relevant genomic alterations and to aid in classification of rare subtypes

**Abstract:** 4520

**Poster Board:** 190

**Poster Display Location:** S Hall A

**Poster Discussion Location:** E Arie Crown Theatre

**Session:** Genitourinary (Nonprostate) Cancer

**Presenter:** Sumanta Kumar Pal, M.D., City of Hope

**Collaborators:** City of Hope, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Oncology Service and Oncology Research Unit - HSL/PUCRS

**Date & Time:** Saturday, May 30, 2015 from 1:15-4:45 p.m. CT

**Title:** Awaiting Comprehensive genomic profiling of cervical squamous cell carcinoma to identify targeted therapy options

**Abstract:** 5602

**Poster Board:** 160

**Location:** S Hall A

**Session:** Gynecological Cancer

**Presenter:** Julia Andrea Elvin, M.D., Ph.D., pathologist, Foundation Medicine

**Collaborators:** Northwestern University, Sarah Cannon Research Institute, Northwestern Medicine Developmental Therapeutics Institute, Albany Medical College, Stanford University

**Date & Time:** Saturday, May 30, 2015 from 1:15-4:45 p.m. CT

**Title:** Comprehensive genomic profiling of salivary gland adenocarcinomas to reveal a high frequency of druggable targets

**Abstract:** 6040

**Poster Board:** 363

**Location:** S Hall A

**Session:** Head and Neck Cancer

**Presenter:** Matthew J. Hawryluk, Ph.D., vice president, corporate and business development, Foundation Medicine

**Collaborator:** Albany Medical College

**Date & Time:** Sunday, May 31, 2015 from 8:00-11:30 a.m. CT

**Title:** Germline variants in cancer risk genes detected by NGS-based comprehensive tumor genomic profiling (CGP)

**Abstract:** 11084

**Poster Board:** 298

**Location:** S Hall A

**Session:** Tumor Biology

**Presenter:** Michael J. Hall, M.D., Fox Chase Cancer Center

**Collaborator:** Fox Chase Cancer Center

**Date & Time:** Sunday, May 31, 2015 from 8:00-11:30 a.m. CT

**Title:** Genomics of young lung cancer study

**Abstract:** TPS11110

**Poster Board:** 324b

**Location:** S Hall A

**Session:** Tumor Biology

**Presenter:** Barbara J. Gitlitz, M.D., University of Southern California Keck School of Medicine

**Collaborators:** University of Southern California Keck School of Medicine, Addario Lung Cancer Medical Institute, Dana-Farber Cancer Institute

**Date & Time:** Monday, June 1, 2015 from 8:00-11:30 a.m. CT

**Title:** Comprehensive genomic profiling of anal squamous cell carcinoma to reveal frequency of clinically relevant genomic alterations in the PI3K/mTOR pathway

**Abstract:** 3522

**Poster Board:** 14

**Location:** S Hall

**Session:** Gastrointestinal (Colorectal) Cancer

**Presenter:** Eric M. Sanford, senior research associate, Foundation Medicine

**Collaborator:** Albany Medical College

**Date & Time:** Monday, June 1, 2015 from 8:00-11:30 a.m. CT

**Title:** Comprehensive genomic profiling of clinically advanced colorectal carcinoma to reveal frequent opportunities for targeted therapies

**Abstract:** 3553

**Poster Board:** 45

**Location:** S Hall A

**Session:** Gastrointestinal (Colorectal) Cancer

**Presenter:** Jeffrey S. Ross, M.D., medical director, Foundation Medicine

**Collaborator:** Albany Medical College

**Date & Time:** Monday, June 1 2015 from 8:00-11:30 a.m. CT

**Title:** Genomic analysis of colitis-associated cancers

**Abstract:** 3566

**Poster Board:** 58

**Location:** S Hall A

**Session:** Gastrointestinal (Colorectal) Cancer

**Presenter:** Rona D. Yaeger, M.D., Memorial Sloan Kettering Cancer Center

**Collaborators:** Memorial Sloan Kettering Cancer Center, The Children's Hospital of Philadelphia

**Date & Time:** Monday, June 1, 2015 from 1:15-4:45 p.m. CT

**Title:** Analysis of BRAF alterations and molecular profiling in glioblastoma and astrocytoma

**Abstract:** 2074

**Poster Board:** 64

**Location:** S Hall A

**Session:** Central Nervous System Tumors

**Presenter:** Nadia Faiq, University of California San Diego

**Collaborator:** University of California San Diego Moores Cancer Center

**Date & Time:** Monday, June 1, 2015 from 1:15-4:45 p.m. CT  
**Title:** Comprehensive genomic profiling of rare tumors in dedicated community clinic  
**Abstract:** 6540  
**Poster Board:** 97  
**Locations:** S Hall  
**Presenter:** William Jeffrey Edenfield, M.D., Greenville Health System  
**Collaborator:** Institute for Translational Oncology Research - Greenville Health System

**Date & Time:** Monday, June 1, 2015 from 1:15-4:45 p.m. CT  
**Title:** Prospective clinical study of precision oncology in solid tumors  
**Abstract:** 6585  
**Poster Board:** 142  
**Location:** S Hall A  
**Presenter:** Davendra Sohal, M.D., Cleveland Clinic  
**Collaborators:** Cleveland Clinic Taussig Cancer Institute, University of Virginia School of Medicine, University of Illinois Chicago

**Date & Time:** Monday, June 1, 2015 from 1:15-4:45 p.m. CT  
**Title:** Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder to reveal frequency of clinically relevant genomic alterations  
**Abstract:** 4526  
**Poster Board:** 196  
**Location:** S Hall A  
**Session:** Genitourinary (Nonprostate) Cancer  
**Presenter:** Matthew J. Hawryluk, Ph.D., vice president, corporate and business development, Foundation Medicine  
**Collaborators:** The Urological Institute of Northeastern New York, Albany Medical Center, Albany Medical College

**Date & Time:** Monday, June 1, 2015 from 1:15-4:45 p.m. CT  
**Title:** Amplification of CRKL in human cancer: A rare event associated with potential sensitivity to targeted therapy  
**Abstract:** 1526  
**Poster Board:** 350  
**Location:** S Hall A  
**Session:** Cancer Prevention, Genetics, and Epidemiology  
**Presenter:** Kai Wang, M.D., Ph.D., senior scientist, technical supervisor, clinical next generation sequencing, Foundation Medicine  
**Collaborators:** Huntsman Cancer Institute - University of Utah, Albany Medical College

**Date & Time:** Monday, June 1, 2015 from 1:15-4:45 p.m. CT  
**Title:** Comprehensive genomic profiling of advanced stage esophageal squamous cell carcinomas (ESCC) and esophageal adenocarcinomas (EAC)  
**Abstract:** 1535  
**Poster Board:** 359  
**Location:** S Hall A  
**Session:** Cancer Prevention, Genetics, and Epidemiology  
**Presenter:** Kai Wang, M.D., Ph.D., senior scientist, technical supervisor, Foundation Medicine  
**Collaborator:** Albany Medical College

**Date & Time:** Monday, June 1, 2015 from 1:15-4:45 p.m. CT  
**Title:** Intratumoral heterogeneity of cancer driver genomic alterations across several tumor types  
**Abstract:** 1558  
**Poster Board:** 382  
**Location:** S Hall A  
**Session:** Cancer Prevention, Genetic, and Epidemiology  
**Presenter:** Kai Wang, M.D., Ph.D., senior scientist, technical supervisor, Foundation Medicine  
**Collaborator:** Albany Medical College

**Date & Time:** Monday, June 1, 2015 from 1:15-4:45 p.m. CT  
**Title:** Hereditary implications of somatic tumor testing  
**Abstract:** 1523  
**Poster Board:** 347  
**Location:** S Hall A  
**Presenter:** Pauline Funchain, M.D., Cleveland Clinic  
**Collaborators:** Cleveland Clinic Taussig Cancer Institute, University of Virginia School of Medicine

## About Foundation Medicine

Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit <http://www.FoundationMedicine.com> or follow Foundation Medicine on Twitter (@FoundationATCG).

*Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.*

## Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of molecular information to guide identification, characterization and treatment of cancer, including difficult cancers; the ability of comprehensive genomic profiling, including FoundationOne and FoundationOne Heme, to identify genomic alterations and improve patient outcomes; and the clinical relevance of comprehensive genomic profiling in cancer treatment and the development of targeted therapies. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risk that FoundationOne and Foundation Medicine's molecular information platform will not be able to identify genomic alterations in the same manner as prior clinical data, and the risks described under the caption "Risk Factors" in Foundation Medicine's Annual Report on Form 10-K for the year ended December 31, 2014, which is on file with the Securities and Exchange Commission, as well as other risks detailed in subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20150518005617/en/>

### Media Contact:

Pure Communications, Inc.  
Dan Budwick, 973-271-6085  
[dan@purecommunicationsinc.com](mailto:dan@purecommunicationsinc.com)

or

### Investor Contact:

Susan Hager, 617-418-2258  
[ir@foundationmedicine.com](mailto:ir@foundationmedicine.com)

or

Matt Clawson, 949-370-8500  
[matt@purecommunicationsinc.com](mailto:matt@purecommunicationsinc.com)

Source: Foundation Medicine, Inc.

News Provided by Acquire Media